Scott Kellen - 01 Jun 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship: CFO and Secretary
Issuer ticker: DMAC
Reported as of: 01 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2022, 17:02:32 UTC
Prior SEC filing: 16 Aug 2021
Next SEC filing: 02 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Amy Culbert, attorney-in-fact

Key filing fact

Scott Kellen filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 02 Jun 2022.

Key facts

This page summarizes Scott Kellen's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2022, 17:02.

Change

Previous filing in this sequence was filed on 16 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC holding

Voting Common Shares, no par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 22,290
Date: 01 Jun 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMAC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 01 Jun 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 60,000
Exercise price: $2.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Vests with respect to 25% of the underlying common shares on June 1, 2023 and with respect to the remaining 75% of the underlying common shares in 36 as nearly equal as possible monthly installments commencing on July 1, 2023.